• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Pelago Secures $58M to Expand Substance Use Management as an Employee Benefit

by Syed Hamza Sohail 03/29/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Pelago Secures $58M to Expand Substance Use Management as an Employee Benefit

What You Should Know:

  • Pelago the leading digital clinic partner to U.S. businesses and health plans for substance use management, today announced $58 million in new funding on the strength of customer growth and validated ROI
  • Existing investor Atomico doubled down to lead this Series C investment on the back of Pelago’s impressive growth, with participation from all existing investors Kinnevik AB, Octopus Ventures, and Y Combinator plus new investor Eight Roads.

Advancing Substance Use Management: Pelago’s Impact on Healthcare Costs and Treatment Efficacy

The raised additional capital will enable Pelago to expedite its product roadmap, expand its continuum of care, enhance digital engagement strategies, and progress its clinical research initiatives. In conjunction with this funding round, Atomico Partner Laura Connell will join Pelago’s board.

Pelago was established with the fundamental belief that substance use is a manageable chronic condition. The company is actively tackling the escalating rates and expenses associated with substance misuse through its 100% fees-at-risk model, which not only yields improved outcomes but also demonstrates a return on investment (ROI). Given the escalating healthcare expenditures, employers and health plans are increasingly prioritizing value, cost-efficiency, and outcome-driven care for their employees and members. Surveys conducted by consulting firms Mercer and WTW indicate that workplace health plan costs are projected to surge by over 6% in 2024. Furthermore, recent research from the Centers for Disease Control and Prevention reveals that the annual minimum direct cost of substance use disorders stands at $15,640 per affected employee enrolled in employer-sponsored insurance, totaling over $35 billion annually.

In a groundbreaking analysis of medical claims focusing on substance use management, Pelago’s program demonstrated a yearly reduction in medical claims of $9,367 per participant compared to a control group, resulting in a 3.0x ROI. Over 80% of the cost savings identified in Pelago’s analysis were attributed to decreased medical expenditure, with the remainder linked to reduced behavioral health costs.

Research indicates that in non-specialized substance use disorder (SUD) treatment environments, up to 89% of adults with SUDs may remain undetected, leading to treatment delays, relapses, and increased expenses. Moreover, for those who do receive SUD treatment in mental health settings, the treatment provided often fails to address their specialized SUD needs. Meanwhile, the adverse financial and productivity impacts persist hidden within medical claims and absenteeism, significantly affecting a company’s bottom line through costly health issues, inpatient and outpatient care, inefficient utilization management, and diminished productivity.

“I’m so proud of the work we have done to improve lives and expand access to substance use care that works. We empower employers and payers to bring our solution to their members struggling with tobacco, alcohol or opioids, from prevention to treatment and recovery.” said Pelago CEO and Co-Founder Yusuf Sherwani, M.D. “We’re addressing a gap in the market left by employee assistance programs and mental health benefits providers who are unable to detect and treat substance use disorders. Customers are resonating with our solution as evidenced by a tenfold growth in revenue and eligible lives since our Series B two years ago.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

'Cranky Index' Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

‘Cranky Index’ Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Chipiron Secures $17M to Transform MRI Access with Portable Scanner

Chipiron Secures $17M to Transform MRI Access with Portable Scanner

Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR

Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR

5 Ways New Trump Administration Tariffs Are Impacting U.S. Healthcare Now

5 Ways Trump Administration Tariffs Are Impacting U.S. Healthcare Now

iCAD, GE HealthCare Integrate to Advance Breast Cancer Detection with AI

RadNet to Acquire iCAD for $103M in All-Stock Transaction

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |